Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Pharmaceutical Deal Trends 2017 Factbook: Partnerships and Acquisitions Shift Focus Towards Early Stage Development, Emerging Markets, and Biolo
Publication Date Jul 2017
Product Type Report
Single User License help $ 2995.00
Site User License help $ 5990.00
Corporate User License help $ 8985.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

Although the pharmaceutical market is continuing to witness global growth, pharmaceutical and biotechnology companies are facing challenges due to disruptive events in the healthcare market, such as increasing costs of production and R&D, shifts in patent laws, and challenges in the economy. Companies are considering various strategies to overcome these challenges, with deal making being foremost among these as a means of boosting revenues over a short period of time.

Small companies that primarily carry out early-stage research, development and production activities are entering into agreements with key industry leaders to out-license the rights to their products, utilizing the strengths of the larger companies in terms of commercialization expertise, manufacturing, distribution and marketing capabilities and global presence. Additionally, many companies have successfully implemented deal-making strategies to secure extended protection for their products from generic competitors. Deal activity can help pharma companies to enhance their research and regulatory approaches, and can aid portfolio expansion and diversification, geographic expansion, entry into niche markets, commercialization, and sales.

This report analyzes the importance of deal making in the pharmaceutical and healthcare market. It covers key factors that encourage deal activity in the pharmaceutical industry, and the key strategies being implemented when companies strike deals. An overview of recent deal activity from 2010 to May 2017 is also included.
Scope

    What deal making strategies have been used in recent years to boost R&D productivity and allow the successful commercialization of pharmaceutical products?

    In which geographical markets and disease areas has deal activity been focused since 2010?

    At which stage of development did deals most frequently occur, and attract the highest value?

    How have pharma companies been using deal making to strengthen their product portfolio and bottom line?

    What are the most significant Mergers and Acquisitions (M&As), licensing deals and partnership deals to have been announced since 2016?

    Who are the major players in pharmaceutical deal making, and what has been their recent and key deal activity?

Reasons To Buy

    Gain a comprehensive understanding of the most recent healthcare deal trends.

    Understand the most significant M&As, licensing deals and partnerships to have occurred in recent years.

    Comprehensively analyze the trends of deal activity from 2010 to May 2017, with respect to aggregate deal value, geography, and the therapy area and stage of development of the products involved.

    Understand the deal-making strategies that have been historically implemented by companies, and identify the most suitable strategies for boosting R&D portfolio and bottom line performance.

    Identify the key deal terminations that have occurred in recent years, and understand their effect.


Table of Contents

Introduction

Overview

Factors Promoting Deal Activity

Key Strategies Implemented in Deals

Geographical Expansion

Portfolio Enhancement

Market Consolidation

Improving Research and Development

Product Lifecycle management

Entry into Rare disease Markets

Deal Types

Mergers and Acquisitions (M&As)

Overview

Key Announced Deals in M&As

Terminated M&As

Asset Swaps

Key Asset Swaps

Partnerships

Overview

Key Announced Deals

Terminated Partnerships

Licensing

Overview

Key Announced Deals

Terminated Licensing deals

Overview of Pharmaceutical Deals from 2010 to 2016

Pharmaceutical Deals by Value and Year

Number of Deals by Region/Country

Number of Deals by Prominent Therapy Area

Number of Deals by Stage of Development

Number of Deals by Molecule Type

Number of deals and Value by Type of Deal

Key Players

Conclusions and Future Scope

Bibliography

Title Date Price
Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report
By QYResearch
The Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Digital Camera Head for Endoscopes industry. The re ...Read More
Apr 2016 $3600.00
Global Dental Laboratory Handpieces Consumption 2016 Market Research Report
By QYResearch
The Global Dental Laboratory Handpieces Consumption 2016 Market Research Report is a professional and in-depth study on the current state of the Dental Laboratory Handpieces market. First, the report ...Read More
Jan 2016 $4000.00
Back to Report Store Home Cardiovascular Disorders Drug Development Pipeline Review, 2017
By GBI Research
Description Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dys ...Read More
Mar 2017 $3995.00
Back to Report Store Home Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes
By GBI Research
Pain, and in particular chronic pain, is a significant global health issue. While pain is not considered a disease in its own right, there is a growing body of evidence that substantiates chronic pain ...Read More
Aug 2016 $6995.00
Back to Report Store Home Frontier Pharma: Dermatology - Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation
By GBI Research
Description Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 distinct dermatological conditions are thought to exist, ranging from rare a ...Read More
Jun 2017 $6995.00
Back to Report Store Home Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation
By GBI Research
Description Globally, liver cancer is the sixth most common cancer, but its poor prognosis makes it the second leading cause of cancer-related death (Globocan, 2012). Currently, the range of therapi ...Read More
Jun 2017 $6995.00
Back to Report Store Home Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation
By GBI Research
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a ...Read More
Aug 2016 $6995.00
Back to Report Store Home Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential
By GBI Research
Immunology is a large therapy area characterized by disorders of the immune system – specifically an aberrant immune response against healthy tissues present in the body, leading to chronic or a ...Read More
Jan 2017 $6995.00
Back to Report Store Home Global Immunology Drugs Market to 2022-Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth
By GBI Research
Immunology is a therapy area characterized by disorders of the immune system, specifically an aberrant autoimmune response against healthy tissues in the body, leading to chronic or acute inflammation ...Read More
May 2017 $4995.00
Back to Report Store Home Innovation and Clinical Trial Tracking Factbook 2017: An Assessment of the Pharmaceutical Pipeline
By GBI Research
GBI Research’s latest report: “Innovation and Clinical Trial Tracking Factbook 2017: An Assessment of the Pharmaceutical Pipeline” is a comprehensive, granular analysis of the 25,522 ...Read More
May 2017 $2995.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

Published By :  GBI Research

For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z